Reportlinker.com

Reportlinker.com

June 25, 2008 19:55 ET

Examine the Lipitor Market Analysis and Forecasts Report, 2007-2012, 2017 and 2023

LONDON, UNITED KINGDOM--(Marketwire - June 25, 2008) - Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue.

Lipitor Market analysis and forecasts Report, 2007-2012, 2017 and 2023

http://www.reportlinker.com/p090277/Lipitor-Market-analysis-and-forecasts-Report-2007-2012-2017-and-2023.html

In 2006, Pfizer's Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co's Zocor and Zetia, Astrazeneca's Crestor, Abbott's Tricor and Bristol Myers Squibb's Pravacol.

However, as Lipitor's blockbuster revenue is seriously threatened by imminent patent expiration in some of the drug's largest markets such as the US, Japan and the UK, there is significant unrest between Pfizer's key stakeholders about the future of the drug. Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1 billion annual drug sales or more, as well as the fast expanding generic market in which India's Ranbaxy is a dominant force.

What questions does the report answer?

- Has the success of Pfizer's Lipitor been overstated?

- Did Pfizer create a monster in Lipitor?

- Have Lipitor sales redefined the bounds that pharmaceutical margins can now reach?

- How imminent is Lipitor patent expiration?

- Which key markets will suffer the consequence of Lipitor expiry?

- Is Ranbaxy ready for generic Lipitor?

- Do the fast developing markets, CEE and the Latin America segment hold the key to future sales after Lipitor's patent expiration?

- Is Lipitor a victim of the struggling Blockbuster Model?

- What is next for Lipitor?

- Do the fast developing markets, CEE and Latin America segment hold the key to future sales after Lipitor's patent expiration?

- Is Lipitor, a victim of the struggling Blockbuster Model?

- What is next for Lipitor?

As Pfizer's Lipitor struggles to fend off the immediate entry of Ranbaxy's generic Lipitor, in key markets, the legal challenges surrounding the number one drug have set a new benchmark for pharmaceutical companies protecting branded products. Industry observers including Visiongain predicts that Pfizer's crises are far from over, as the high revenue streams of Lipitor will experience significant challenges before the commencement of the next decade.

Moreover, Pfizer's lack of success to replace Lipitor with Torcetrapib has escalated the company's near-term battles besides the ever-tighter regulatory hurdles, reduced R&D efficiency and increased competition, creating formidable therapeutic challenges as healthcare payers influence pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, the rising incidence of multiple diseases, ageing populations, the rising living standards and fast-developing geographical markets. The future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period of economic changes and pressures.

This report includes detailed five-year forecasts over the period 2008-2013, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This unique in-depth management report examines the future prospects for Lipitor from 2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven major markets (7MM). This detailed report highlights the most compelling must know issues- Lipitor's patent contention by Pfizer in both 7MM and other markets in order to block Ranbaxy's immediate penetration of generic Lipitor. In light of healthcare drug bills increasing exponentially, generic Lipitor will be welcomed by managed care organisations (MCO) and further widen the generic revenue margins, visiongain concludes. This report also tackles Lipitor's significant developments, potential opportunities on the market and important contemporary matters, especially commercial drivers and restraints.

Unique benefits to you when you order this report:

- Primary research throughout: you will not find this information anywhere else

- Full searchable report when you buy the company or corporate editions

- Easily downloadable copies of the report available for offline reading

- The report is filled with detailed charts, analysis, figures, graphs and tables

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


1 Executive Summary 
1.1 Lipitor Was the World's Best Selling Drug In 2006 
1.2 Lipitor Will Face Strong Competition After Patent Expiration In Key 
Markets 
1.3 Lipitor Is Embroiled In Patent Challenges With Ranbaxy 
2 Overview of Lipitor (Atorvastatin) 
2.1 Lipitor (Atorvastatin) - The Cholesterol Reducing Drug 


2.1.1 Pfizer Acquires Lipitor After Merging With Warner-Lambert 
2.1.2 Dyslipidemia 


2.1.2.1 Classification of Dyslipidaemia 

2.1.3 Dyslipidaemia - a Major Risk Factor In Developing Coronary Heart 
Disease In The Western Population 
2.1.4 Aetiology of Dyslipidaemia 


2.1.4.1 Primary Causes of Dyslipidemia 
2.1.4.2 Secondary Causes of Dyslipidaemia 
2.1.4.3 Diabetes A Leading Cause of Secondary Dyslipidaemia 

2.2 Obesity Is a Major Environmental Factor Associated With Dyslipidaemia 


2.2.1 Strong Link Between Diabetes And Obesity 
2.2.2 Diet Remains An Important Component In Regulating Lipid levels 
2.2.3 Behaviour 
2.2.4 Regular Physical Exercise 

2.3 Symptoms and Signs of Dyslipidaemia 
2.4 Diagnosis, Screening and Markers of Dyslipidaemia 


2.4.1 Direct Measurement of Total cholesterol, Triglycerides, And HDL 
2.4.2 Estimation of Low-density Lipoprotein (LDL) And Very Low-Density 
Lipoprotein (VLDL) 
2.4.3 Fasting Lipid Profile 
2.4.4 Screening Patients Under 20 Years For Atherosclerotic Risk Factors 
2.4.5 Screening For Lipoprotein(a) levels 

3 Treatment of Dyslipidaemia 
3.1 Lipid Regulating Drugs Are Central To Treating Dyslipidaemia 


3.1.1 Statins are First Choice Lipid-Regulating Drugs 
3.1.2 Statin Drugs Are Significant Market for Leading Pharmaceutical 
Companies 
3.1.3 Lipitor A Second-Generation 3-hydroxy-3-methygulutaryl coenzyme A 
(HMGCoA) Reductase Inhibitor Gold Standard Drug 

3.2 Posology And Method of Administration of Lipitor 


3.2.1 Primary Hypercholesterolaemia and Combined (Mixed) Hyperlipidaemia 
In Adults And Children aged 10-17 years 


3.2.1.1 Heterozygous Familial Hypercholesterolaemia in Adults and Children 
aged 10-17 years 
3.2.1.2 Homozygous Familial Hypercholesterolaemia in Adults and Children 
aged 10-17 years 
3.2.1.3 Lipitor Dosage in Patients With Renal Insufficiency 
3.2.1.4 Lipitor Dosage in Patients With Hepatic Dysfunction 
3.2.1.5 Lipitor Dosage in Geriatric 

4 Lipitor World Market Analysis 
4.1 Lipid-regulating/ Anti-Atheroma Preparations Is The Largest In 
Cardiovascular System Market 


4.1.1 Pfizer Is The Leader In Cardiovascular Pharmaceuticals 
4.1.2 Cholesterol And Triglycerides Reduction Drugs Generate Highest 
Individual Sales 
4.1.3 The US Market For Cholesterol and Triglyceride Drugs Sees The 
largest Sales 

4.2 Lipitor (Atorvastatin) Revenue Dominates all Cholesterol & 
Triglyceride Drugs 


4.2.1 Lipitor Sales in North America, Europe, Africa, Asia & Australasia 
and Latin America 


4.2.1.1 Lipitor Sales are Most Significant In US 
4.2.1.2 Lipitor Drives Sales For Cholesterol & Triglyceride Reducers In 
The EU Market 
4.2.1.3 UK is Lipitor's Largest Market In Europe 
4.2.1.4 Lipitor Sales Decline in France 
4.2.1.5 Lipitor Sales Grow By 10% In 2006 
4.2.1.6 Lipitor Experiences Strong Market Growth In Italy 
4.2.1.7 Lipitor Year-on-Year Sales Decline Continued In Germany 
4.2.1.8 Japan is Lipitor's Strongest Market in Africa, Asia & Australasia 

4.3 Lipitor's Faces Competitions From Key Rivals In Major Markets 


4.3.1 Lipitor's Prescription Volume Eroded Steeply Due To Generic Statins 
4.3.2 AstraZeneca's Crestor, Merck & Co and Schering Plough's Vytorin 
Dampens Lipitor's Market Share 
4.3.3 Head-to-Head Clinical Study Proves Lipitor to Be More Potent Than 
Crestor 
4.3.4 Vytorin A Strong Contender For Market Share With Lipitor During 
Near-Term 

4.4 Pfizer's Lipitor Challenge With Ranbaxy Will Have Significant 
Implications On Future Sales 
4.5 US WellPoint Demonstrates Generic Statins- Lovastatin, Simvastatin 
And Pravastatin To Elicit Cardiovascular Benefits 
4.6 Lipitor Global Sales Forecast 2008-2023 


4.6.1 Lipitor's Five New Indications Will Be key To Sales Growth After 
Patent Expiration 
4.6.2 Lipitor Major Market Sales Forecast 2008-2023 
4.6.3 US Lipitor Market Forecasts 2008-2023 
4.6.4 Japan Lipitor Market Forecast 2008-2023 
4.6.5 EU Lipitor Market Forecast 2008-2023 
4.6.6 UK Lipitor Market Forecast 2008-2023 
4.6.7 France Lipitor Market Forecast 2008-2023 
4.6.8 Spain Lipitor Market Forecast 2008-2023 
4.6.9 Italy Lipitor Market Forecast 2008-2023 
4.6.10 Germany Lipitor Market Forecast 2008-2023 

4.7 Lipitor Competes With Other Non-Statin Drugs 


4.7.1 Bristol Myers Questran Is leading Anion Exchange Resin 
4.7.2 MSD and Schering-Plough's Ezetrol An Adjunct Therapy for Inhibiting 
Absorption of Cholesterol 
4.7.3 Fibrates Constitute A Significant Market 
4.7.4 Niaspan Is Key Nicotinic Acid Competitor To Lipitor 
4.7.5 Simcor- Niaspan And Generic Simivastatin Will Increase Lipitor 
Competition 
4.7.6 US National Heart, Lung and Blood Institute Sponsors Niaspan And 
Simvastatin AIM-HIGH Study 
4.7.7 Fish Oils Industry A Growing Market and A deterrent To Lipitor Growth 

4.8 Pfizer Has Large Resources To Promo 
5. Lipitor's Key Patent Challenges 
5.1 Patent Expiration is the Major Driver in All Generic Markets 
5.2 The US Has The Largest Generics Market 
5.3 The US and European Regulation of Generic Drugs 
5.4 Pfizer's Lipitor Patent Protection Sets Benchmark In Pharmaceutical 
Industry For Protecting Brands 
5.5 Pfizer Struggles To Block Early Generic Lipitor Market Entry 
5.6 The Hatch-Waxman Act, Patent Expiration and the Promotion of Generic 
Drugs: Title I of the Act 


5.6.1 Ranbaxy To Benefit From The Hatch-Waxman Title I 
5.6.2 US First To Market 180-Day Exclusivity Period Incentive Will Be Key 
To Rambaxy's Initial Sales Success of Generic Atorvastatin 

5.7 Ranbaxy Receives Favourable Lipitor Decisions in Key EU Markets 


5.7.1 Federal Patent Court of Germany Revokes Lipitor Patent 

5.8 Lipitor Expanding Patent Contention 


5.8.1 Pfizer Versus Teva Pharmaceuticals' ANDA For Generic Atorvastatin 
5.8.2 Pfizer Versus Cobalt Pharmaceuticals For Atorvastatin Sodium A 
Potentially Marketable Product 
5.8.3 Pfizer Vs Apotex Generic Atorvastatin In Canada 

5.9 Ranbaxy Will Cover Cost of Legal Challenges From Sales of Atorvastatin 
in Key Markets 

6 Lipitor- Product Life Cycle Management (PML) 
6.1 Pfizer To Use Product Lifecycle Management to Drive Sales of Lipitor 
6.2 Pfizer's Prominent PLM Is Caduet- ``uber-pill``, a combination of 
Lipitor And Norvasc 


6.2.1 Caduet Sales Rises Significantly By 99% in 2006 

6.3 Pfizer's Torcetrapib- The Lipitor Follow-Up Drug Fails To Deliver 
6.4 Pfizer Lipitor and Peripheral Vascular Diseases 
6.5 Pfizer's LEAD Trial investigates Lipitor in Combination with Aricept 
in AD patients 
6.6. Other Lipitor Significant Clinical Studies 


6.6.1 Lipitor Pre-Clinical Data 


6.6.1.1 Atorvastatin Proves to be More Liver Selective Than Pravastatin 

6.6.2 Atorvastastin Clinical Data 


6.6.2.1 Atorvastatin Was Tolerated in Healthy Volunteers 

6.7 Cardiovascular Disease 


6.7.1 Ten milligram (10 mg) of Atorvastatin Has Significant Effect 
Lipid-Lowering Ability 
6.7.2 Coronary Artery Disease-AVERT (Atorvastatin Versus 
Revascularization Treatment) 
6.7.3 Ten milligram (10 mg) Atorvastatin is Effective in Australian 
Atorvastatin Assessment Study 
6.7.4 Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering 
(MIRACL) Study 
6.7.5 ASCOT trial Demonstrates Atorvastatin to Reduce Risk of Heart Attack 
Induced by Hypertension 
6.7.6 Head-To-Head REVERSAL Trial Demonstrates that Highest Dose of 
Atorvastatin, Halted Atherosclerosis 
6.7.7 Post-Hoc Analysis in Treating New Targets (TNT ) Trial Demonstrates 
Atorvastatin 80 mg with Less Cardiovascular Events Than 10 mg dose 
6.7.8 Atorvastatin - Incremental Decrease in Endpoints Through Aggressive 
Lipid Lowering (IDEAL) Trial Reveals Significantly Fewer Risk of Secondary 
Heart Attacks 
6.7.9 CARDS study (Collaborative AtoRvastatin Diabetes Study)-Shows Marked 
Reduction in Percentages Risk of Cardiovascular Events in Diabetes Patients 
6.7.10 SPARCL study (Stroke Prevention by Aggressive Reduction in 
Cholesterol Study) 
6.7.11 Atorvastatin Lowers Cardiovascular Disease By a Significant 
Percentage 

6.8 Paediatric Studies Demonstrated Significant Therapeutic benefits of 
Lipitor 
6.9 Lipitor Post Marketing Studies 
7 Lipitor Competitor Studies & Pipeline 
7.1 Lipitor worldwide clinical studies 
7.2 Competitor Agents in Development 


7.2.1 Abbott And AstraZeneca's Developmental Fibrate /Cholesterol reducing 
Agent Shows Significant Potential 
7.2.2 First Horizon's Fenofibrate (Triglide) And Aegerion's MTP Inhibitor 
(AEGR 733) 

8 Lipitor SWOT Analysis 
8.1 Lipitor First Drug of Choice For Cholesterol Treatment 
8.2 Lipid Regulator Market Will Continue to Generate High Revenues 
8.3 An Expanding Patient Population Constitutes the Principal Driver in 
the Statins Market 
8.4 Changes to Treatment Guidelines in US and Europe Can Benefit Sales Of 
Lipitor 
8.5 The US Market Will Continue To Be Key for Lipitor's Sales Growth 
8.6 Generic Rivals Will Drive The Erosion of Lipitor's Market Share 


8.6.1 The US has the Largest Generics Market 
8.6.2 Generic Statins A Growing Presence In The US Market 
8.6.3 Rising Generic Uptake in Key EU Markets Will Impact On Lipitor Sales 
8.6.4 Generic Statins Potential Threat To Lipitor Growth As They Become 
Mainstay In Japan 

8.7 Pfizer And Astellas Reach Lipitor Settlement In Japan 
8.8 US and EU Two -Year Statin Approval Timelines Increase Competitiveness 
8.9 Lipitor A Testimony of The Crumbling Blockbuster Business Model 
8.10 Pfizer Will Need Strategies That Will Yield High ROI After Lipitor's 
Patent Expiration 
8.11 New Reformulation Will be Significant To Drive Lipitor 's Long-Term 
Revenues 
8.12 Liptor Still Has Significant Developmental Possibilities 
8.13 Lipitor's Prominent Indications For Diverse Cardiovascular and 
Metabolic Areas Will be Significant For Future Sales 
8.14 Lipitor Significant Trial Results Will Drive Sales 
8.15 Is Pfizer's Lipitor Success Repeatable? 
8.16 US House of Democrats Investigate Lipitor's Director-To-Customer 
Advertisement Campaign 
8.17 OTC Simvastatin Adds To Lipitor's Competition 
8.18 Anti-Counterfeiting Initiatives Will Safeguard Lipitor in Emerging 
Markets 
8.19 Lipitor Will Face Pricing Competition From Generic Statins 
9 Conclusion 
9.1 Lipitor (Atorvastatin) - The Cholesterol Reducing Drug 
9.2 Lipid-regulating Drugs Generate The Highest Revenues In Cardiovascular 
Market 
9.3 Statin Drugs Are Significant Market for Leading Pharmaceutical 
Companies 
9.4 Lipitor (Atorvastatin) Is The World's Highest Selling Drug 
9.5 Lipitor Sales Are Most Significant In the US Market 


9.5.1 Lipitor Sales in other Key Markets 
9.5.2 Lipitor Global Sales Forecast 2008-2023 

9.6 Lipitor's Faces Competition From Key Rivals 
9.7 Non-Statin Drug Therapies Market Expands 
9.8 Pfizer Using Product Lifecycle Management to Drive Sales of Lipitor 
9.9 Caduet Positioned To Experience Strong Sales After Lipitor Expiration 
9.10 Ranbaxy's Successsful Patent Lawsuits Against Pfizer In Key Markets 
Will Be Costly To Lipitor's Future Sales 
9.11 Visiongain Concludes that Loyalty from Pfizer and Brand ``Lipitor's`` 
Key Stakeholders Will Confer Future Sales 
List of Tables 
Table 2.1 Lipoprotein Patterns (Fredrickson Phenotypes) 
Table 2.2 Genetic Variations In Dyslipidaemia 
Table 2.3 Obese Population in Major Countries by Percentage (%) 
Table 4.1 Sales Distribution of Cardiovascular Disease Market, 2006 
Table 4.2 Leading Companies in Cardiovascular Market, 2006 
Table 4.3 Sales Distribution of Leading Anti-Atheroma Therapies, 2006 
Table 4.4 Leading Markets In Cholesterol and Triglyceride Drugs 
Table 4.5 Global Sales of Top Ten Leading Statin Drugs, 2006 
Table 4.6 Market Share of Lipitor in leading Markets, 2003-2006 
Table 4.7 Lipitor Sales in Key EU Markets, 2003-2006 
Table 4.8 Comparison of Effects on Cholesterol Levels 
Table 4.9 Comparison of Dose Effects on LDL Cholesterol (LDL-C) 
Table 4.10 Lipitor (Atorvastatin) Patents Expiration In Major Markets 
Table 4.11 Lipitor Global Sales Forecast 2008-2023 
Table 4.12 US Lipitor Global Sales Forecast 2008-2023 
Table 4.13 Japan Lipitor Global Sales Forecast 2008-2023 
Table 4.14 UK Lipitor Global Sales Forecast 2008-2023 
Table 4.15 France Lipitor Global Sales Forecast 2008-2023 
Table 4.16 Spain Lipitor Market Forecasts 2008-2023 
Table 4.17 Italy Lipitor Market Forecasts 2008-2023 
Table 4.18 Lipitor Sales In Germany, 2003-2006 
Table 4.19 Germany Lipitor Market Forecasts 2008-2023 
Table 4.20 Leading Fibrate Drugs, 2006 
Table 4.21 Leading Anti-atheroma Preparations Of Natural Origin (Fish Oil 
Products), 2006 
Table 5.1 The Top Ten US Generic Drugs by Revenue ($m) and Units, 2006 
Table 5.2 US Top Ten Generic Drugs as a Function of Combined Branded and 
Generic Drugs by Prescription Number (m) and Revenues ($m),2006 
Table.5.3 Prescription Number (m), 2004 Top 10 Generic Drugs, Dispensed by 
Prescriptions in the US, 2006 
Table 5.4 Lipitor (Atorvastatin) Patents In Major Markets 
Table 5.5 Ranbaxy /Pfizer (Atorvastatin) Patents Challenges In Other Markets
Table 6.1 Pfizer Post Marketing Lipitor Studies 
Table 6.2 Pfizer's Lipitor Phase III Studies 
Table 7.1 Competitors Post Marketing Cardiovascular Agents Studies Including
Lipitor 
Table 7.2 Competitors Comparative Phase III Cardiovascular Agents Including 
Lipitor 
Table 7.3 Competitors Comparative Phase II Cardiovascular Agents Including 
Lipitor 
Table 7.4 Competitors Comparative Phase I Cardiovascular Agents Including 
Lipitor 
Table 7.5 Competitors Other Comparative Cardiovascular Agents Including 
Lipitor 
Table 8.1 Lipitor Market SWOT Analysis 
List of Figures 
Figure 1.1 Market Shares of Leading Statin Drugs, 2006 
Figure 1.2 Lipitor Sales in key leading markets, 2003-2006 
Figure 1.3 Lipitor Market Share in key leading markets, 2003-2006 
Figure 4.1 Sales Distribution of Cardiovascular Disease Market, 2006 
Figure 4.2 Leading Companies in Cardiovascular Market, 2006 
Figure 4.3 Sales Distribution of Leading Anti-Atheroma Therapies, 2006 
Figure 4.4 Leading Markets Share In Cholesterol and Triglyceride Drugs 
Figure 4.5 Sales Distribution of Top Ten Leading Statin Drugs, 2006 
Figure 4.6 Sales Distribution of Top Five Leading Statin Drugs, 2006 
Figure 4.7 Market Share of Lipitor in leading Markets, 2006 
Figure 4.8 Lipitor Sales in Key EU Market, 2006 
Figure 4.9 Market Share of Lipitor in Key EU Market, 2006 
Figure 4.10 Lipitor Global Sales Forecast 2008-2023 
Figure 4.11 US Lipitor Market Forecasts 2008-2023 
Figure 4.12 Japan Lipitor Market Forecasts 2008-2023 
Figure 4.13 UK Lipitor Market Forecasts 2008-2023 
Figure 4.14 France Lipitor Market Forecasts 2008-2023 
Figure 4.15 Spain Lipitor Market Forecasts 2008-2023 
Figure 4.16 Italy Lipitor Market Forecasts 2008-2023 
Figure 4.17 Lipitor Sales In Germany, 2003-2006 
Figure 4.18 Germany Lipitor Market Forecasts 2008-2023


More Details

Organisations mentioned in this report: 
Abant Izzet Baysal University 
Abbott 
Actavis 
Aegerion Pharmaceuticals 
American College of Clinical Pharmacy 
American Heart Association 
and Cardiovascular Health 
Apotex 
ASKA Pharmaceutical 
Astellas 
AstraZeneca 
Basic GmbH 
Beside Health 
Beth Israel Deaconess Medical Centre 
Biovail 
Boston University 
Bristol Myers Squibb 
Buddhist Tzu Chi General Hospital 
Canadian Heart Research Centre 
Cardiovascular Institute and Fuwai Hospital 
Chiesi 
Children's Hospital of Philadelphia 
Children's Mercy Hospital Kansas City 
Cipla 
CNAM (Conservatoire National des Arts et Métiers) 
Cobalt Pharmaceuticals 
Daiichi Sankyo 
Damon Runyon Cancer Research Foundation 
DiObex 
Emory University 
FDA Office of Orphan Products Development 
First Horizon 
Gedeon Richter 
GlaxoSmithKline 
Global Pharmaceuticals 
Hartford Hospital,CT USA 
Hospital de Clinicas de Porto Alegre 
Japan Foundation for the Promotion of International Medical Research 
Cooperation 
Kaken 
Korea University Anam Hospital 
Kos Pharmaceuticals 
LifeCycle Pharma 
Lupin 
M.D. Anderson Cancer Centre 
Maine Centre for Lipids 
Masaryk University 
Mayo Clinic 
McGill University Health Centre 
Medical College of Wisconsin 
Medical Research Council 
Medical University of South Carolina 
Memorial Sloan-Kettering 
Merck & Co 
Merck KGaA 
Ministry of Science and Higher Education, Poland 
MSD 
National Cancer Institute (NCI) 
National Centre for Research Resources (NCRR) 
National Heart, Lung and Blood Institute (NHLBI) 
National Institute of Allergy and Infectious Disease (NIAID) 
National Institutes of Health (NIH) 
National Science Council, Taiwan 
National Taiwan University Hospital 
New York University School of Medicine 
NHS Greater Glasgow and Clyde 
Nobel 
Novartis 
Ontario Association of Optometrists 
Ontario Thoracic Society 
OrbusNeich 
Par Pharmaceuticals 
Park-Davis 
Penn State University 
Pfizer 
Pharma Nord 
Queen's University 
Queen's University 
R&D Cardiologie UMC Utrecht 
Radboud University 
Ranbaxy 
Rikshospitalet-Radiumhospitalet 
Roche 
Samsung Medical Centre 
Sanofi-Aventis 
Schering Plough 
Sciele 
Servier 
Seven Seas 
Shenyang Northern Hospital 
Shenyang Northern Hospital 
Silesian School of Medicine 
SkyePharm 
Solvay 
St Vincent's University Hospital, Ireland 
St. Michael's Hospital, Toronto 
Stanford University 
Sun Pharma 
Tanabe 
Teijan 
Teofarma 
Teva Pharmaceuticals 
The Centre for Rheumatic Disease Allergy, & Immunology Saint Luke's 
Hospital 
The Cleveland Clinic 
The Gustavus and Louise Pfeiffer Research Foundation 
The Hospital of Vestfold 
The Netherlands Organisation for Health Research and Development 
The Physicians' Services Incorporated Foundation 
Toronto Ophthalmological Society 
Università degli Studi dell'Insubria 
University Hospital, Brest 
University Hospital, Motol 
University of Calgary Heart and Stroke Foundation of Ontario 
University of California 
University of Campinas 
University of Chicago 
University of Florida 
University of Glasgow 
University of North Carolina 
University of Oslo 
University of Oslo School of Pharmacy 
University of Toronto 
University of Wisconsin, Madison 
VU University Medical Centre 
Warner-Lambert 
WellPoint 
Yokohama City University Medical Centre

To order this report:

Lipitor Market analysis and forecasts Report, 2007-2012, 2017 and 2023

http://www.reportlinker.com/p090277/Lipitor-Market-analysis-and-forecasts-Report-2007-2012-2017-and-2023.html

More market research reports here!

Contact Information